电针与普芦卡必利治疗超重度慢性便秘:随机对照试验二次分析
该研究为多中心非劣效随机对照试验的二次分析,纳入317例超重度慢性便秘患者(电针组151例,普芦卡必利组166例)。第1至8周两组每周完全自发排便次数增加相似(差值-0.02,95%CI -0.34至0.30,非劣效P<0.001)。电针组不良事件少于普芦卡必利组,疗效可能持续24周。
要点
- 电针改善每周完全自发排便次数不劣于普芦卡必利。
- 第1至2周普芦卡必利在增加排便次数等方面效果更优。
- 电针不良事件更少,疗效可能持续24周。
核心结论
- 在超重度慢性便秘患者中,电针改善完全自发排便次数、排便相关症状和生活质量的效果与普芦卡必利相当,且安全性更优。
研究设计与样本
- 多中心非劣效随机对照试验的二次分析,共纳入317例超重度慢性便秘患者,电针组151例,普芦卡必利组166例。
主要发现
- 第1至8周两组每周完全自发排便次数增加相似,差值-0.02(95%CI -0.34至0.30),非劣效P<0.001。
- 第1至2周普芦卡必利组在增加完全自发排便次数、缓解排便困难和改善粪便性状方面优于电针组。
- 电针组不良事件少于普芦卡必利组,电针效果可能持续24周。
关键数值与推荐
- 主要结局为第1至8周平均每周完全自发排便次数,非劣效检验P<0.001。
- 超重度慢性便秘定义为每周无完全自发排便。
临床怎么用
- 电针可作为超重度慢性便秘的替代治疗选择,尤其关注安全性时。
- 早期(第1至2周)可考虑普芦卡必利以更快改善排便症状。
局限性
- 本研究为二次分析,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To explore the effect and safety of electroacupuncture (EA) compared to prucalopride in patients with ultra-severe chronic constipation (USCC), a condition defined by the absence of weekly complete spontaneous bowel movements (CSBMs). METHODS: This study was a secondary analysis using data from a multicenter, non-inferiority randomized controlled trial, involving patients with USCC. Participants received either EA or prucalopride treatment. The primary outcome was the mean weekly CSBMs from weeks 1 to 8. Secondary outcomes included the mean weekly CSBMs, the proportion of overall and weekly responders, changes in straining and stool consistency scores, Patient Assessment of Constipation Quality of Life (PAC-QOL) scores, and the proportion of patients using rescue medication. RESULTS: A total of 317 participants with USCC were included (151 in the EA group and 166 in the prucalopride group). From weeks 1 to 8, both groups showed similar increases in the CSBMs (difference: -0.02; 95% confidence interval [CI], -0.34 to 0.30, P < 0.001 for noninferiority). However, during weeks 1 to 2, the prucalopride group showed greater effects than the EA group in increasing CSBMs, alleviating defecation difficulties, and improving stool consistency. The EA group experienced fewer adverse events (AEs) than the prucalopride group. CONCLUSIONS: In participants with USCC, EA showed improvements in CSBMs, defecation-related symptoms, and quality of life that were comparable to those observed with prucalopride. The effects of EA might persist for 24 weeks, and EA exhibited a superior safety profile. TRIAL REGISTRATION NUMBER: NCT02047045 (ClinicalTrials.gov).
引用
- Gao S, Zhu L, Yao H, et al. Effect of electroacupuncture versus prucalopride for ultra-severe chronic constipation: Secondary analysis of a randomized controlled trial. Integr Med Res. 2025. PMID: 41080507. doi:10.1016/j.imr.2025.101253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。